Cargando…
ZAR1 is a novel epigenetically inactivated tumour suppressor in lung cancer
BACKGROUND: Lung cancer is the leading cause of cancer-related deaths with 1.8 million new cases each year and poor 5-year prognosis. Promoter hypermethylation of tumour suppressors leads to their inactivation and thereby can promote cancer development and progression. RESULTS: In this study, we ana...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5457737/ https://www.ncbi.nlm.nih.gov/pubmed/28588743 http://dx.doi.org/10.1186/s13148-017-0360-4 |
_version_ | 1783241599668453376 |
---|---|
author | Richter, Antje M. Kiehl, Steffen Köger, Nicole Breuer, Janina Stiewe, Thorsten Dammann, Reinhard H. |
author_facet | Richter, Antje M. Kiehl, Steffen Köger, Nicole Breuer, Janina Stiewe, Thorsten Dammann, Reinhard H. |
author_sort | Richter, Antje M. |
collection | PubMed |
description | BACKGROUND: Lung cancer is the leading cause of cancer-related deaths with 1.8 million new cases each year and poor 5-year prognosis. Promoter hypermethylation of tumour suppressors leads to their inactivation and thereby can promote cancer development and progression. RESULTS: In this study, we analysed ZAR1 (zygote arrest 1), which has been said to be a maternal-effect gene and its expression mostly limited to certain reproductive tissues. Our study shows that ZAR1 is expressed in normal lung but inactivated by promoter methylation in lung cancer. ZAR1 is hypermethylated in primary lung cancer samples (22% small cell lung carcinoma (SCLC) and 76% non-small cell lung carcinoma (NSCLC), p < 0.001) vs. normal control lung tissue (11%). In lung cancer cell lines, ZAR1 was significantly methylated in 75% of SCLC and 83% of NSCLC vs. normal tissue (p < 0.005/0.05). In matching tumours and control tissues, we observed that NSCLC primary tumour samples exhibited a tumour-specific promoter methylation of ZAR1 in comparison to the normal control lung tissue. Demethylation treatment of various lung cancer cell lines reversed ZAR1 promoter hypermethylation and subsequently re-established ZAR1 expression. In addition, we could show the growth inhibitory potential of ZAR1 in lung cancer cell lines and cancer cell lines. Exogenous expression of ZAR1 not only inhibited colony formation but also blocked cell cycle progression of cancer cell lines. CONCLUSIONS: Our study shows for the first time the lung tumour-specific epigenetic inactivation of ZAR1 due to DNA methylation of its CpG island promoter. Furthermore, ZAR1 was characterised by the ability to block tumour growth through the inhibition of cell cycle progression in cancer cell lines. We propose that ZAR1 could serve as an epigenetically inactivated biomarker in lung cancer. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13148-017-0360-4) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5457737 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-54577372017-06-06 ZAR1 is a novel epigenetically inactivated tumour suppressor in lung cancer Richter, Antje M. Kiehl, Steffen Köger, Nicole Breuer, Janina Stiewe, Thorsten Dammann, Reinhard H. Clin Epigenetics Research BACKGROUND: Lung cancer is the leading cause of cancer-related deaths with 1.8 million new cases each year and poor 5-year prognosis. Promoter hypermethylation of tumour suppressors leads to their inactivation and thereby can promote cancer development and progression. RESULTS: In this study, we analysed ZAR1 (zygote arrest 1), which has been said to be a maternal-effect gene and its expression mostly limited to certain reproductive tissues. Our study shows that ZAR1 is expressed in normal lung but inactivated by promoter methylation in lung cancer. ZAR1 is hypermethylated in primary lung cancer samples (22% small cell lung carcinoma (SCLC) and 76% non-small cell lung carcinoma (NSCLC), p < 0.001) vs. normal control lung tissue (11%). In lung cancer cell lines, ZAR1 was significantly methylated in 75% of SCLC and 83% of NSCLC vs. normal tissue (p < 0.005/0.05). In matching tumours and control tissues, we observed that NSCLC primary tumour samples exhibited a tumour-specific promoter methylation of ZAR1 in comparison to the normal control lung tissue. Demethylation treatment of various lung cancer cell lines reversed ZAR1 promoter hypermethylation and subsequently re-established ZAR1 expression. In addition, we could show the growth inhibitory potential of ZAR1 in lung cancer cell lines and cancer cell lines. Exogenous expression of ZAR1 not only inhibited colony formation but also blocked cell cycle progression of cancer cell lines. CONCLUSIONS: Our study shows for the first time the lung tumour-specific epigenetic inactivation of ZAR1 due to DNA methylation of its CpG island promoter. Furthermore, ZAR1 was characterised by the ability to block tumour growth through the inhibition of cell cycle progression in cancer cell lines. We propose that ZAR1 could serve as an epigenetically inactivated biomarker in lung cancer. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13148-017-0360-4) contains supplementary material, which is available to authorized users. BioMed Central 2017-06-02 /pmc/articles/PMC5457737/ /pubmed/28588743 http://dx.doi.org/10.1186/s13148-017-0360-4 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Richter, Antje M. Kiehl, Steffen Köger, Nicole Breuer, Janina Stiewe, Thorsten Dammann, Reinhard H. ZAR1 is a novel epigenetically inactivated tumour suppressor in lung cancer |
title | ZAR1 is a novel epigenetically inactivated tumour suppressor in lung cancer |
title_full | ZAR1 is a novel epigenetically inactivated tumour suppressor in lung cancer |
title_fullStr | ZAR1 is a novel epigenetically inactivated tumour suppressor in lung cancer |
title_full_unstemmed | ZAR1 is a novel epigenetically inactivated tumour suppressor in lung cancer |
title_short | ZAR1 is a novel epigenetically inactivated tumour suppressor in lung cancer |
title_sort | zar1 is a novel epigenetically inactivated tumour suppressor in lung cancer |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5457737/ https://www.ncbi.nlm.nih.gov/pubmed/28588743 http://dx.doi.org/10.1186/s13148-017-0360-4 |
work_keys_str_mv | AT richterantjem zar1isanovelepigeneticallyinactivatedtumoursuppressorinlungcancer AT kiehlsteffen zar1isanovelepigeneticallyinactivatedtumoursuppressorinlungcancer AT kogernicole zar1isanovelepigeneticallyinactivatedtumoursuppressorinlungcancer AT breuerjanina zar1isanovelepigeneticallyinactivatedtumoursuppressorinlungcancer AT stiewethorsten zar1isanovelepigeneticallyinactivatedtumoursuppressorinlungcancer AT dammannreinhardh zar1isanovelepigeneticallyinactivatedtumoursuppressorinlungcancer |